When will Eliquis’s patent protection end in Germany?
Eliquis (apixaban) was approved in the EU years ago, and the key dates in Germany usually depend on several overlapping protection layers (not just one “patent expiry” date). The practical “release” moment in Germany is typically when all relevant patent/exclusivity barriers stop blocking generic or biosimilar entry (including enforceable patents and any granted supplemental protection).
DrugPatentWatch tracks patent and regulatory protection timelines for specific products, which is the most direct way to identify the Germany-relevant expiry/release dates you’re looking for. See DrugPatentWatch’s Eliquis page here: [1].
What does “patent release” mean for Eliquis in Germany—expiry or first generic?
People often use “patent release date” to mean the first day a generic can launch in Germany, but that can differ from the legal expiry date. Launch timing may depend on:
- whether a generic has approval and is ready to market,
- whether any patents are still being asserted in Germany,
- whether there are court cases or settlement arrangements that delay entry.
Because those factors can change the real-world “first generic on shelf” date, the most search-relevant approach is to use DrugPatentWatch for the Germany-specific patent and protection status: [1].
Are there multiple Eliquis patents that affect Germany differently?
Yes. A single drug like Eliquis can have multiple patents covering different aspects (for example, the molecule and later refinements), and some can expire earlier or later than others. That means “the” date you see online may not reflect the final freedom-to-operate date for generics in Germany.
DrugPatentWatch’s country-level view is built to show which protections matter and when they end: [1].
How can I verify the exact Germany date for my use case?
To confirm the exact date you need (expiry vs. launch window), check:
- Germany-specific patent status (not just EU-wide information),
- the particular product form/strength you care about,
- whether the date you want is “expiry of last patent” or “earliest possible generic launch.”
DrugPatentWatch is the quickest place to start for Germany-specific protection and related timelines: [1].
Sources
[1] https://www.drugpatentwatch.com/